These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 35396243)

  • 1. Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance.
    Ernst T; Aebi S; Zander A; Zander T
    BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35396243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
    Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin AM; Le N; Patel K; Flaherty K
    N Engl J Med; 2014 Nov; 371(20):1877-88. PubMed ID: 25265492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
    Johnson DB; Flaherty KT; Weber JS; Infante JR; Kim KB; Kefford RF; Hamid O; Schuchter L; Cebon J; Sharfman WH; McWilliams RR; Sznol M; Lawrence DP; Gibney GT; Burris HA; Falchook GS; Algazi A; Lewis K; Long GV; Patel K; Ibrahim N; Sun P; Little S; Cunningham E; Sosman JA; Daud A; Gonzalez R
    J Clin Oncol; 2014 Nov; 32(33):3697-704. PubMed ID: 25287827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
    Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
    Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
    Flaherty KT; Infante JR; Daud A; Gonzalez R; Kefford RF; Sosman J; Hamid O; Schuchter L; Cebon J; Ibrahim N; Kudchadkar R; Burris HA; Falchook G; Algazi A; Lewis K; Long GV; Puzanov I; Lebowitz P; Singh A; Little S; Sun P; Allred A; Ouellet D; Kim KB; Patel K; Weber J
    N Engl J Med; 2012 Nov; 367(18):1694-703. PubMed ID: 23020132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
    Zeng Q; Deng Y; Zhang L; Wang W
    Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
    Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
    Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
    Marks AM; Bindra RS; DiLuna ML; Huttner A; Jairam V; Kahle KT; Kieran MW
    Pediatr Blood Cancer; 2018 May; 65(5):e26969. PubMed ID: 29380516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
    Bourque MS; Salek M; Sabin ND; Canale M; Upadhyaya SA
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28814. PubMed ID: 33211390
    [No Abstract]   [Full Text] [Related]  

  • 14. CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.
    Da Vià MC; Solimando AG; Garitano-Trojaola A; Barrio S; Munawar U; Strifler S; Haertle L; Rhodes N; Teufel E; Vogt C; Lapa C; Beilhack A; Rasche L; Einsele H; Kortüm KM
    Oncologist; 2020 Feb; 25(2):112-118. PubMed ID: 32043788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
    Queirolo P; Picasso V; Spagnolo F
    Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.
    Mooradian MJ; Cleary JM; Giobbie-Hurder A; Darville LNF; Parikh A; Buchbinder EI; Cohen JV; Lawrence DP; Shapiro GI; Keer H; Chen HX; Ivy SP; Smalley KSM; Koomen JM; Sullivan RJ
    Cancer; 2023 Jun; 129(12):1904-1918. PubMed ID: 37042037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabrafenib plus trametinib in patients with BRAF
    Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
    Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
    Meng P; Koopman B; Kok K; Ter Elst A; Schuuring E; van Kempen LC; Timens W; Hiltermann TJN; Groen HJM; van den Berg A; van der Wekken AJ
    Lung Cancer; 2020 Aug; 146():358-361. PubMed ID: 32534795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.
    Awada G; Schwarze JK; Tijtgat J; Fasolino G; Kruse V; Neyns B
    Melanoma Res; 2022 Jun; 32(3):183-191. PubMed ID: 35377866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.